Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer

Penile squamous cell carcinoma is genomically similar to other HPV-driven tumours

Updates from the BCON trial: Longterm outcomes of hypoxia modification in bladder preservation

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC

CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma

ASCO GU 2019 renal highlights

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC